Pegcetacoplan slows geographic atrophy growth but carries risk of exudative AMD
For patients with age-related macular degeneration (AMD), intravitreal injections of pegcetacoplan reduce the rate of geographic atrophy (GA) growth but appear to be associated with an unexpected dose-dependent increase in the incidence of new-onset exudative (e)AMD, according to data from the phase II FILLY trial.
